fig1

Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions

Figure 1. FDA-approved drugs for multiple myeloma and date of their first approval.

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/